Remifentanil's effect is not prolonged in a patient with pseudocholinesterase deficiency

Anesthesia and Analgesia

Volumn 89, Issue 2, 1999, Pages 529-530

  Manullang, Jocelyn ^a   Egan, Talmage D ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE; MIVACURIUM; REMIFENTANIL; SUXAMETHONIUM;

ADULT; ANESTHETIC RECOVERY; ARTICLE; ARTIFICIAL VENTILATION; CASE REPORT; DRUG EFFECT; ENZYME DEFICIENCY; FEMALE; HUMAN; PRIORITY JOURNAL;

EID: 0032812063     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-199908000-00053     Document Type: Article

References (10)

1. Egan TD. Remifentanil pharmacokinetics and pharmacodynamics: a preliminary appraisal. Clin Pharmacokinet 1995;29:80-94.
2. Pantuck EJ. Plasma cholinesterase: gene and variations. Anesth Analg 1993;77:380-6.
3. Petersen RS, Bailey PL, Kalameghan R, Ashwood ER. Prolonged neuromuscular block after mivacurium. Anesth Analg 1993;76: 194-6.
4. Davis L, Britten JJ, Morgan M. Cholinesterase: its significance in anaesthetic practice. Anaesthesia 1997;52:244-60.
5. Deleted in proof.
6. Deleted in proof.
7. Achari R, Drissel D, Matier WL, Hulse JD. Metabolism and urinary excretion of esmolol in humans. J Clin Pharmacol 1986; 26:44-7.
8. Rosow C. Remifentanil. a unique opioid analgesic. Anesthesiology 1993;79:875-6.
9. Smith MA, Morgan M. Remifentanil. Anaesthesia 1997;52:291-3.
10. Thompson JP, Rowbotham DJ. Remifentanil: an opioid for the 21st century. Br J Anaesth 1996;76:341-3.